SUPERNUS PHARMACEUTICALS, INC. 4

Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals (SUPN), received 750 shares of common stock upon vesting of Performance Share Units on July 29, 2026.

On July 29, 2026, Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals, Inc., had 750 shares of common stock credited to him upon the vesting of previously granted Performance Share Units. The award relates to PSUs originally granted on February 19, 2025, which partially vested based on the achievement of individual performance objectives established on May 3, 2025. This is a non-open-market, compensation-related equity award, and the Form 4 indicates that Rubin now directly owns 750 shares of Supernus common stock following this vesting event. No sale or purchase for cash consideration occurred, and no per-share price is provided in the filing, so the dollar value of the transaction and resulting holdings must be considered modest and routine in nature.

Filing Facts

CIK

1356576

Ticker

SUPN

Form

4

Source Type

fda

Accession

0001836067-26-000008

Alert Tier

4